AKT1 and endometrial cancer: Aurora-A triggers the AKT/mTOR pathway in endometrial cancer, which stimulates cell proliferation and causes chemoresistance, suggesting that Aurora-A inhibitor and AKT/mTOR inhibitor in combination with chemotherapy intervention may be a therapeutic strategy for Aurora-A overexpressed endometrial cancer (87).